77 related articles for article (PubMed ID: 3987835)
1. Correlation of hematologic toxicity of antineoplastic agents with their effects on bone marrow stem cells: interspecies studies using an in vivo assay.
Marsh JC
Exp Hematol; 1985; 13 Suppl 16():16-22. PubMed ID: 3987835
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Marsh JC; Brown BJ; Nierenburg MM
Cancer Res; 1983 Jun; 43(6):2962-6. PubMed ID: 6573955
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the sensitivities of human, canine, and murine hematopoietic precursor cells to adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Marsh JC
Cancer Res; 1979 Feb; 39(2 Pt 1):360-4. PubMed ID: 761207
[TBL] [Abstract][Full Text] [Related]
4. The sensitivities of human and murine hemopoietic cells exposed to cytotoxic drugs in an in vivo culture system.
Gordon MY; Blackett N
Cancer Res; 1976 Aug; 36(8):2822-6. PubMed ID: 1277192
[TBL] [Abstract][Full Text] [Related]
5. Normalization of in vitro sensitivity testing of human tumor clonogenic cells.
Hug V; Thames H; Blumenschein GR; Spitzer G; Drewinko B
Cancer Res; 1984 Mar; 44(3):923-8. PubMed ID: 6692414
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells.
Marsh JC
Cancer Treat Rep; 1982 Mar; 66(3):499-504. PubMed ID: 6460555
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of cytotoxic agents on hematopoietic progenitors.
Botnick LE; Hannon EC; Vigneulle R; Hellman S
Cancer Res; 1981 Jun; 41(6):2338-42. PubMed ID: 7237432
[TBL] [Abstract][Full Text] [Related]
8. 2'3'-Dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow.
Irons RD; Le AT; Som DB; Stillman WS
J Clin Invest; 1995 Jun; 95(6):2777-82. PubMed ID: 7539460
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic sensitivity of normal and leukemic hematopoietic progenitor cells to N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide, a new anticancer agent.
Spiro TE; Socquet M; Delforge A; Stryckmans P
J Natl Cancer Inst; 1981 Apr; 66(4):615-8. PubMed ID: 6939909
[TBL] [Abstract][Full Text] [Related]
10. Hemopoietic progenitor cells in the blood as indicators of the functional status of the bone marrow after total-body and partial-body irradiation: experiences from studies in dogs.
Nothdurft W; Kreja L
Stem Cells; 1998; 16 Suppl 1():97-111. PubMed ID: 11012152
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
van Tellingen O; Nooijen WJ; Schaaf LJ; van der Valk M; van Asperen J; Henrar RE; Beijnen JH
Cancer Res; 1998 Jun; 58(11):2410-6. PubMed ID: 9622082
[TBL] [Abstract][Full Text] [Related]
12. Dose-survival curves of cis-platinum, melphalan, and velban in human granulocyte/macrophage progenitor cells.
Umbach GE; Singletary SE; Tomasovic B; Spitzer G; Hug V; Drewinko B
Int J Cell Cloning; 1984 Nov; 2(6):335-40. PubMed ID: 6542929
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal.
van Os R; Robinson S; Sheridan T; Mauch PM
Stem Cells; 2000; 18(2):120-7. PubMed ID: 10742384
[TBL] [Abstract][Full Text] [Related]
14. [Effect of hydroxyurea on the number of hematopoietic stem cells, stromal cell precursors and cell precursors of thymus lymphoid tissue in the bone marrow of mice during aging].
Sidorenko AV; Andrianova LF
Tsitologiia; 1984 Jul; 26(7):813-7. PubMed ID: 6485091
[TBL] [Abstract][Full Text] [Related]
15. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
Fairbairn LJ; Chinnasamy N; Lashford LS; Chinnasamy D; Rafferty JA
Cancer Gene Ther; 2000 Feb; 7(2):233-9. PubMed ID: 10770631
[TBL] [Abstract][Full Text] [Related]
16. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
18. Methods for measuring suppression of hematopoiesis.
Chervenick PA
Exp Hematol; 1985; 13 Suppl 16():8-15. PubMed ID: 3987838
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions.
Cardier JE; Erickson-Miller CL; Murphy MJ
Stem Cells; 1997; 15(4):286-90. PubMed ID: 9253112
[TBL] [Abstract][Full Text] [Related]
20. The A.H.E.A.D. method: a quantitative automated measurement of the hematotoxicity of anticancer drugs.
Saint-Dizier D; Sancier M; Cudennec CA
Anticancer Res; 1990; 10(3):765-71. PubMed ID: 2369090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
